Miramoon Pharma — Seed (estimated)

Pinama Capital announced an investment of undisclosed size in Miramoon Pharma, which is developing treatments to stop degenerative diseases, starting with retinitis pigmentosa. No stage was given; this is filed as Seed because it follows the November 2025 seed round and comes before the Phase I round the company planned to open in Q1 2026. It may be a seed extension or the first close of that 2026 round.